Please note
This trial is no longer recruiting patients. We hope to add results when they are available.
Lung cancer, Non small cell lung cancer (NSCLC)
Closed
Phase 2
This study is looking at lorlatinib for non small cell lung cancer (NSCLC) that has a change in a called anaplastic lymphoma kinase (ALK). This is called ALK positive disease.
It is open to people whose cancer got worse during treatment with one of the following:
ceritinib
alectinib
brigatinib
If you are still having treatment with one of the above and it is still working you may be able to join a that is part of this study.
Recruitment start: 29 September 2022
Recruitment end: 1 July 2023
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Fiona Blackhall
European Organisation for Research and Treatment of Cancer (EORTC)
Last reviewed: 05 Sept 2023
CRUK internal database number: 19164
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
What to ask your doctor about clinical trials.
Meet and chat to other cancer people affected by cancer.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
